Donald Levy, MD
Allergy & Immunology · Orange, CANPI 1518055011
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $126,388 of the $206,737 with a category attached, or 61.1%. 38 manufacturers reported payments, led by CSL Behring at 51.4% of the total. Among allergy & immunology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,095 payments — averaging $188.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$106K
- Biocryst US Sales Co., LLC$42K
- Shire North American Group Inc$16K
- Biocryst Pharmaceuticals, Inc.$12K
- Takeda Pharmaceuticals U.S.A., Inc.$10K
- Pharming Healthcare, Inc.$5K
- plus $15K from 32 others
Across 155 payments — averaging $1283.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$199K
What the payments were for
- Consulting fees$39,15319%
- Speaking & faculty fees$126,38861%
- Travel & lodging$15,4337%
- Food & beverage$25,49512%
- Education$2680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 218 | $106,363 |
| Biocryst US Sales Co., LLC | 109 | $41,605 |
| Shire North American Group Inc | 35 | $16,247 |
| Biocryst Pharmaceuticals, Inc. | 35 | $12,150 |
| Takeda Pharmaceuticals U.S.A., Inc. | 97 | $10,013 |
| Pharming Healthcare, Inc. | 40 | $5,057 |
| Sanofi | 76 | $3,232 |
| AstraZeneca | 99 | $2,320 |
| GSK | 107 | $1,723 |
| Cycle Pharmaceuticals Inc | 5 | $1,331 |
| Optinose US, Inc. | 28 | $1,265 |
| Regeneron Healthcare Solutions, Inc. | 49 | $1,229 |
| Grifols USA, LLC | 32 | $810 |
| Boehringer Ingelheim | 25 | $447 |
| Pfizer | 22 | $422 |
| Mylan Specialty L.p. | 19 | $405 |
| Novartis | 11 | $243 |
| ARS Pharmaceuticals Operations, Inc. | 11 | $212 |
| Viatris Specialty LLC | 12 | $211 |
| LEO Pharma Inc. | 7 | $207 |
| Amgen(2 entities) | 5 | $191 |
| Kyowa Kirin, Inc. | 2 | $184 |
| Teva Pharmaceuticals USA, Inc. | 18 | $175 |
| Genentech USA, Inc. | 6 | $121 |
| Aquestive Therapeutics, Inc. | 1 | $119 |
| Incyte Corporation | 6 | $109 |
| Ionis Pharmaceuticals, Inc. | 4 | $87 |
| Covis Pharma GmbH | 3 | $51 |
| Kaleo, Inc. | 3 | $44 |
| Hikma Pharmaceuticals USA | 2 | $32 |
| Verona Pharma, Inc. | 1 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $25 |
| Phadia US Inc. | 1 | $20 |
| Arcutis Biotherapeutics, Inc. | 1 | $15 |
| Alk-abello, Inc | 1 | $13 |
| Merck | 1 | $13 |
| Octapharma USA, Inc. | 1 | $12 |
| Organon | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$206,737 in reported general payments places this provider in the 95th percentile of 426 allergy & immunology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 14 | $149,762 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 134 | $95,129 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 17 | $86,713 |
| Spiriva RespimatTiotropium Bromide | 41 | $30,504 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $29,663 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $8,228 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $7,668 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $5,535 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 39 | $4,530 |
| Azelastine Hcl | 158 | $4,462 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 34 | $3,960 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $3,930 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $3,564 |
| Ipratropium Bromide | 92 | $3,167 |
| Wixela InhubFluticasone Propion/Salmeterol | 32 | $2,369 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,723 | $266,322193 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,320 | $33,22652 claims |
| Boehringer IngelheimSpiriva Respimat | $447 | $30,50441 claims |
| Hikma Pharmaceuticals USAEpinephrine | $32 | $1,81913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 426 allergy & immunology providers in California.
Other allergy & immunology in Orange
- Wan-Yin ChanOrange$19K
- Raffi TachdjianSanta Monica$3.7M
- Bob GengSan Diego$3.3M
- Vinay MehtaLaguna Niguel$1.3M
- Andrew WhiteSan Diego$752K
- Marc RiedlSan Diego$725K
- Katharine WoessnerSan Diego$581K
- Brian Modenala Jolla$453K
- Heena Shah PatelUpland$428K
- Jacob OffenbergerGranada Hills$419K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.